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A vaccine inducing protective immunity in mucosal tissues and secretions may stop or limit HIV infection. Although cytotoxic T
lymphocytes (CTLs) are clearly associated with control of viral replication in HIV and simian immunodeﬁciency virus (SIV)
infections, there are examples of uncontrolled viral replication in the face of strong CD8+ T-cell responses. The number of
functions,breadth,avidity,andmagnitudeofCTLresponsearelikelytobeimportantfactorsintheeﬀectivenessofanti-HIVT-cell
response, but the location and persistence of eﬀector CD8+ T cells are also critical factors. Although the only HIV vaccine clinical
trial targeting cellular immunity to prevent HIV infection failed, vaccine strategies using persistent agents against pathogenic
mucosal challenge in macaque models are showing unique success. Thus, the key to control the initial focus of viral replication at
the portal of entry may rely on the continuous generation of eﬀector CTL responses at mucosal level.
1.Introduction
Cytotoxic T lymphocytes (CTLs) play a signiﬁcant role con-
trolling viral replication in HIV and simian immunodeﬁ-
c i e n c yv i r u s( S I V )i n f e c t i o n sa se x e m p l i ﬁ e db yd i v e r s ef a c t s
such as the association of Gag-speciﬁc CTL activity and
viremia or progression to AIDS [1, 2], the viral escape
consequence of immune selection [3, 4]o rb ye n h a n c e dC T L
function in elite controllers (EC) [5–8]. In macaque models,
this association has been reinforced by depletion studies [9–
11] or by studying the mechanisms of protection in live,
attenuated SIV vaccine models [12, 13].
Yet, not all AIDS vaccines that have shown induction
of strong speciﬁc T-cell responses are protective or assure
eﬀective control of HIV/SIV [14, 15]. Factors, both intrinsic
and extrinsic to CTLs, may be critical for determining
the ability of CD8+ T cells to eﬀectively control HIV/SIV
replication. Several intrinsic parameters—inherent to the
CTL response—have been shown to correlate with control
of viremia and/or disease progression (TCR repertoire and
public clonotypes, avidity, polyfunctionality, killing capacity,
etc.) [16–18].
Extrinsic factors aﬀecting the CTL response such as the
inﬂammatory and regulatory environment also determine
the quality and persistence of CD8+ T cells. These external
factors aﬀect the ratio between target cells and eﬀector cells
[19] or inﬂuence the phenotype and functionality of CD8+
eﬀector cells [17, 20], all contributing to viral control. From
animal model studies, we are learning that the generation
and maintenance of a CTL response that is located at
the mucosal site of viral transmission is beneﬁcial against
mucosal challenge with pathogenic SIVmac [12, 21].
2. QualitativeAspects of the CTL Response
CD8+ T lymphocytes interact with virus-infected cells by
recognizing viral peptides presented on the cell surface by
major histocompatibility complex class I molecules. Once
this cognate interaction occurs, there is induction of numer-
ous genes involved in cell cycle, proliferation, apoptosis, and
cytokine secretion. If this interaction induces killing of the
virus-infected target cell, this can occur through two main
pathways [7, 22]. CTLs can bind to receptors of the tumor
necrosis factor superfamily (e.g., Fas-mediated killing) on
the surface of the target cells or deliver the contents of
cytotoxic granules to these target cells, both cases ultimately
inducing cell death. Not only is the granule-independent2 Journal of Biomedicine and Biotechnology
pathway involving Fas/FasL interaction a less frequent mode
of target cell killing, but also during HIV and SIV infections
this pathway is highly activated and contributes to reduced
cellular immunity and disease progression by activation-
induced cell death of bystander cells [23]. The second
pathway is mediated by perforin, which promotes granzyme
delivery to the target cell cytosol, substrate cleavage, and
cell death induction. Lately several papers have reported
enhanced cytotoxic function in HIV-speciﬁc CD8+ Tc e l l s
from EC [7, 22], including a superior ability to express
perforin and granzyme B, with no detectable diﬀerence in
the levels of granzyme A or granulysin, and the transcription
factor T bet is the enhancer of this eﬀector activity [7].
Degranulatingcapacityatmucosallevel,measuredbyCD107
expression, has also been associated with protection against
vaginal challenge with SIV [24], where at early timepoints
after challenge there was signiﬁcantly less degranulation
capacity in the vaginal CD8+ T cells of control animals than
in the immunized macaques. Moreover, CD8+ Tc e l l sf r o m
mucosal tissues may be more eﬃcient at suppressing viral
replication ex vivo than cells from blood [13]. Interestingly,
compared to prime-boost regimens, vaccination with live,
attenuated SIV resulted in a faster kinetics of cytolysis by
SIV-speciﬁc CTLs, with rapid and robust degranulation and
granzymeBreleasefromtetramer-positiveCD8+ Tcells[25].
All these ﬁndings suggest that mucosal CTL mechanisms are
contributing to the success of live, attenuated vaccines. Yet,
we need to determine if all the speciﬁc molecules involved in
these cytotoxic mechanisms are expressed at suﬃcient levels
in the genital mucosa. This is important because CTLs from
the gastrointestinal (GI) mucosa express low perforin [26],
and measurement of CD107 could be overestimating CTL
function if lacking other components. CD107 is expressed
on the CTL surface when the lytic granules are discharged
during target-cell lysis, thus CD107 staining quantiﬁes the
recent killing history of CTLs. But the ability of CD8+ T
cells to induce target cell death is dependent on granule
protein content rather than on the act of degranulation itself
[27]. Still previous studies have shown that the presence of
CD107+ T cells correlated well with cytotoxic activity [28]
and, although CTLs from the GI tract contain low perforin,
an increase in the levels of perforin in gut accompanies the
appearance of the SIV-speciﬁc CD8+ T-cell response during
acute SIV infection [26].
The qualitative aspects of the T-cell response and specif-
ically the capacity of revealing multiple functions upon
antigen stimulation is currently seen as one of the best
correlates of T-cell immunity measurable directly ex vivo
[16],sincepreservationofpolyfunctionalHIV-speciﬁcCD8+
Tcellsisassociatedwithcontrolofviremiaininfectedpeople
[29] and with protection from uncontrolled viral replication
in vaccinated rhesus monkeys after SIV infection [30]. Poly-
functional CD8+ T cells degranulate and produce multiple
functional molecules, such as interleukin-2, interferon-γ,
and tumor necrosis factor. Importantly, this correlation is
also reported in mucosal tissues, where polyfunctional Gag-
speciﬁc CD8+ T cells are signiﬁcantly more abundant in rec-
tal mucosa from controllers as compared to noncontrollers
and patients under antiretroviral therapy [6] or in the genital
tract of the immunized macaques in live, attenuated vaccine
models [24]. Further, the most polyfunctional cells produce
higher levels of cytokine on a per-cell basis [17]. Yet, there is
no consensus on which cytokines and molecules are critical
to control viral replication and, thus, should be measured by
these polychromatic ﬂow cytometry assays [31].
All these features are related to the speciﬁc ligand-
receptor recognition, among other intrinsic parameters,
which are ultimately limited by the T-cell receptor (TCR)
expressed by a particular CTL clone. Studies in this area have
recognized the importance of the TCR repertoire mobilized
against infection and the beneﬁcial eﬀect on vaccine eﬃcacy
of the public composition against viral conserved regions
of these recruited clonotypes [32]. The repertoire engaged
will impact on the breadth of the CTL response (number of
epitopes targeted) and the balance between immunodomi-
nant and subdominant responses, both aﬀecting viral load
[33]. Interestingly, signiﬁcant overlap in the clonality and
immunodominance hierarchy of the CD8+ T cells isolated
from blood and GI mucosa has been demonstrated [26].
Possibly even more crucial, and independent of the
speciﬁc clonotype [34] may be the intensity of the TCR-
mediated signal, which is directly linked to CD8+ T-cell
polyfunctionality and HIV-suppressive activity [16]. CD8+ T
cells with high avidity can recognize low densities of cognate
antigen on the target cell surface, resulting in eﬀective
target cell clearance; which may correspond to a superior
capacitytosuppressHIVreplication[16].Theimportanceof
these high-avidity CTLs on viral dissemination and infection
clearance in animal models, especially of those induced at
mucosal level, has also been established [35]. Further, two
recent studies associate the eﬀectiveness of a CTL response
and their high avidity with a narrow, public clonotypic
repertoire [18, 36]. While recruiting high-avidity clones may
be desirable to promote vaccine eﬃcacy, viral escape is not
impaired [18]. Yet, limiting initial virus replication at the
mucosal level may impair the capacity of escape mutants to
emerge stochastically.
3. Phenotypeof the CTL Response
There is doubt on the importance of the phenotype of the
CD8+ T-cell response in relation to the protective eﬃcacy
in vivo, and little diﬀerence in the functional capacity
when comparing cells across a wide range of phenotypes
has been shown [17, 31]. Still, several aspects related to
extrinsic factors surrounding the speciﬁc response inﬂuence
antigen sensitivity and the functional proﬁle [16]. This way,
viral load and immune activation may induce transient
hyporesponsiveness or cell exhaustion, ultimately generating
less functional CTLs. In fact, antigen load and viral sequence
diversiﬁcation determine the functional proﬁle of HIV-1-
speciﬁc CD8+ T cells [20].
Exhausted T cells express increased amounts of multiple
inhibitory receptors, such as programmed death-1 (PD-
1) among others [37, 38]. PD-1 regulates T-cell activation
and tolerance through mechanisms such as anergy and
development of induced regulatory T cells. The implicationJournal of Biomedicine and Biotechnology 3
of PD-1 on the functional capacity of the CD8+ T-cell
response in chronic viral infections has been widely reported
[37] and sustained antigen-speciﬁc TCR stimulation may
be key to persistent expression of this regulatory molecule
[20]. A recent paper demonstrates that PD-1 can cause T-
cell exhaustion by upregulating a gene that inhibits T-cell
function [39], where enforced expression of basic leucine
transcription factor ATF-like (BATF) was suﬃcient to impair
T-cell proliferation and cytokine secretion. Furthermore,
CD8+ T cells in lymph nodes and Gl mucosa of infected
macaques express high levels of PD-1 while signiﬁcant
reduction in plasma viral load and improved functionality
of these SIV-speciﬁc CD8+ T cells was reached by blocking
PD-1 [40].
Expression of the killer cell lectin-like receptor G1
(KLRG1) on T cells has recently been shown to have a
functional role on human CD8+ T cells inhibiting the
proliferative capacity of highly diﬀerentiated CD8+ Tc e l l s
[41]. Similarly, CD57 is a human natural killer-1 (HNK-1)
glycoprotein found on many NK cells and a subset of CD8+
T cells, where it has been reported to identify terminally
diﬀerentiated T cells with reduced proliferative capacity
[42]. Both these markers have been suggested to identify
replicativesenescentcells,butthefunctionalcapacityandthe
correlation of cells expressing these markers with viral load
in the context of HIV/SIV is unknown. It has been shown
that due to chronic T-cell activation HIV-speciﬁc CD8+
T cells may become replicative senescent, express CD57,
and become prone to activation-induced apoptosis [43].
This may be reﬂective of normal T-cell development during
chronic stimulation and thus not necessarily a defect within
the HIV-speciﬁc CD8+ T cells, since they maintain eﬀective
cytotoxic potential [44, 45]. Moreover, the damage to gut
epithelium may trigger ligation of the inhibitory receptor
KLRG-1 by E-cadherin [46], which inhibits the eﬀector
functions of KLRG1hi-expressing HIV-1-speciﬁc CD8+ T
cells systemically.
It has also been shown that the majority of HIV-speciﬁc
CD8+ T cells are found to express CD57, with or without
PD-1, and that CD57+ PD-1− have higher survival potential
(more resistant to apoptosis) than CD57+ PD-1+.I nf a c t ,
PD-1 has been shown to be a preapoptotic factor for CD8+ T
cells in HIV infection [47, 48]. In a live, attenuated SIV vac-
cine experiment the increased survival potential of the Gag-
speciﬁc CD8+ T cells was associated to control of viremia at
set-point [30], a feature observed in these macaques during
acute infection and restricted to the genital tissue [24]. The
induction of protective prosurvival molecules (members of
the Bcl-2 family) occurs initially through TCR-mediated
speciﬁc activation of T cells, but, as diﬀerentiation proceeds,
this is followed by a decline in Bcl-2 expression and an
increase in cell death signals (i.e., caspases) [49]. However,
the strength of the stimulation determines the level and
duration of Bcl-2 expression [50]. Deﬁning the expression
of these molecules in antiviral T cells may be critical for
understanding the nature of the protective T-cell response.
Although a phenotypic deﬁnition of a protective anti-
SIV/HIV T-cell response is still lacking [31], speciﬁc pheno-
types have been associated with certain functional attributes
[17]. In this sense, HIV-speciﬁc CD8+ T cells in HIV
controllers have a unique HLA-DR+ CD38− phenotype and
the cells of these patients eﬀectively suppress HIV-1 infection
invitro[8].Further,developmentofHLA-DR+ CD38− CD8+
T cells during HIV infection was associated with subsequent
stable CD4+ T-cell levels and good prognosis [51]. CD8+ T
cells from normal uninfected humans express little CD38
or HLA-DR; however, during HIV seroconversion there is
an increase in the subset of cells expressing both markers,
and this activated population probably includes the CTL that
develop during acute HIV infection [52]. The frequency of
T cells expressing CD38 in uninfected rhesus macaques is
higher than in humans and the frequency of HLA-DR+ T
cells is lower in macaques compared to humans. However,
once infected the dynamics of expression on T cell in
humans and macaques and the prognostic value of both
these markers are similar [53]. Interestingly, degranulating
SIV-speciﬁc CD8+ T cells (CD107+)h a v em o r eH L A - D R
expression than the total CD8+ T-cell population in SIV
infected macaques (unpublished data). These ﬁndings are
consistent with the hypothesis that HLA-DR expression on
anti-SIV CD8+ T cells indicates cells with enhanced cytolytic
capacity, as proposed in EC [8]. Similarly, a human vaccine
experiment identiﬁed CD38+, HLA-DR+,K i - 6 7 +, and Bcl-2
low in CD8+ T cells as eﬀector T-cell responses after immu-
nization or infection [54]. By monitoring the expression of
these markers in the blood, they conﬁrmed the increasing
population of eﬀector CD8+ T cells, which correlated with
tetramer and interferon gamma secreting speciﬁc CD8+ T
cells after immunization with live, attenuated yellow fever-
17D vaccine [54].
4. Effects of Antigen PersistenceandLocation
HIV is transmitted primarily by sexual contact, and the
female genital tract, male genital tract, and rectum are the
anatomicsitesofvirustransmission[55].Recentstudieshave
conclusively demonstrated that immediately after mucosal
transmission most systemic HIV and SIV infections are
established by a very limited number of viral envelope vari-
ants [56]. Before virus dissemination occurs, few days after
infection [57], it may be possible to contain and eliminate
these initial founder viral populations at the site by vaccine-
induced eﬀector T cells. Importantly, localized mucosal
memory T-cell populations provide superior control of viral
infection compared with circulating memory T cells. Yet,
since intravaginal or rectal immunization is not a viable
option, we have to think of other ways to establish this
memory mucosal response.
Centralmemory(CM)Tlymphocyteshavelimitedeﬀec-
tor function, but they have the capacity to home and reside
in lymphoid organs and, upon secondary exposure to their
cognate antigen, they rapidly proliferate to become eﬀector
T cells [58]. In contrast, eﬀector memory (EM) T lympho-
cytes home to peripheral tissues and, following antigenic
stimulation, have limited proliferative capacity but have the
ability to degranulate and rapidly produce eﬀector cytokines
[27, 58]. It is reasonable to think that EM-speciﬁc CD8+4 Journal of Biomedicine and Biotechnology
T cells will be more eﬀective at eliminating virus-infected
cells while generating less proinﬂammatory cytokines, thus
attenuating activation and inﬂammatory events. In fact, a
successfulmodeloflive,attenuatedvaccineincreasesthetotal
number of circulating CD8+ T cells [24] and, speciﬁcally,
the EM CD8+ T-cell phenotype (unpublished observations)
while it blunts proliferation, activation, and apoptotic cell
death [12]. Simultaneously, polyfunctional CD8+ Tc e l l s
with high cytotoxic capacity are present in the vagina of
these immunized animals on the day of SIV challenge and
these eﬀector T cells mediate protection in this model [24].
Other successful live, attenuated vaccines elicit mucosal
CTL responses that are more eﬀective at suppressing viral
replication than CD8+ T cells from blood [13]. Similarly to
these models, an immunization strategy using a replication
competent cytomegalovirus (CMV) vector expressing mul-
tiple SIV antigens establishes persistent SIV-speciﬁc EM T-
cell responses at potential sites of SIV replication conferring
protection frommucosal challengein 50% of the immunized
animals [21, 59].
The success of these CMV-vector SIV vaccines and of
live,attenuatedvaccinesindicatesthat,sofar,onlyreplicating
vaccine virus that disseminates throughout the body and
produces antigen continuously, albeit at a low level, in the
mucosal tissues may be capable of providing protective
immunity [12, 13, 21]. While many of the other systemically
administered vaccine strategies may decrease viral replica-
tion after immunized animals become infected, none can
block infection (reviewed in [60]). Several features of these
persistent vaccines that diﬀer from other vaccine strategies
could explain the eﬀectiveness of CD8+ T-cell responses in
these models [12, 13, 21]. Out of these, chronic low-level
of antigenic stimulation from residual vaccine replication
in tissues, including the mucosa aﬀected, up to the time of
challenge and the consequent generation and maintenance
of a resident eﬀe c t i v ea n t i v i r a li m m u n er e s p o n s ea tt h e
portal of virus entry may be the key points to under-
stand protection (Figure 1). This eﬀective antiviral immune
response is characterized by EM CD8+ T cells, which will
help maintain a more homeostatic environment [27, 58].
Then, it is not surprising that these replicating vaccines,
in contrast to other more conventional vaccine strategies
(Figure 1(a)) occurred without anamnestic T-cell responses
[12, 21]. The concept that a persistent, attenuated viral
vaccinethatmaintainsapoolofCD8+ eﬀectorTcellscapable
of controlling but not eliminating the pathogen is necessary
for protection against persisting pathogens like HIV or SIV
was ﬁrst proposed by Zinkernagel [61]. Similarly, in models
of tuberculosis, promising mucosal vaccine systems that
use antigen persistence to generate protective CD8+ Tc e l l s
maintained independently of peripheral supply have been
described [62].
Although the CMV vector vaccine increased resistance to
rectal SIV challenge, virus replication in immunized animals
that became infected was not altered [59]. The immunologic
basis for the all or none protection phenomena seen in this
study remains to be deﬁned but the results are similar to
t h ea l lo rn o n ep r o t e c t i o ns e e ni nb o t hr e c e n t l yc o m p l e t e d
human AIDS vaccine eﬃcacy trials [63–65]. In contrast,
live, attenuated vaccines induce control of viremia when
the infection is productive [66, 67]. This diﬀerence could
be related to some of the requirements of live, attenuated
vaccines to be protective, like the necessity of vigorous
viral replication for the generation of an eﬀective anti-SIV
immune response [68].
5.Target Cell Numberand the CTLResponse
As proposed by Zinkernagel, “protection by immunity
representsanequilibriumbetweenoptimal resistanceagainst
the various cytopathic infections and avoidance of excessive
immunologically mediated tissue damage” [61]. This is
particularly crucial in HIV/SIV infection, since the initial
viral insult initiates an inﬂammatory cascade and immune
activation that, if not resolved soon enough, will contribute
to virus dissemination and infection ampliﬁcation (reviewed
in [69]). In the case of the natural host, immune activation
appears to be detrimental for control of viral replication and
disease progression [70] while EC maintain high levels of
HIV-speciﬁc immune responses with low levels of immune
activation [71].
In this sense, a live, attenuated vaccine model has shown
that the relative number of SIV target cells compared to
the number of SIV vaccine-induced antiviral T cells in the
vagina determines the outcome of vaginal SIV challenge in
immunized animals, since CD8+ T cell-depleted, vaccinated
animalshadthehighestlevelsofSIVreplicationinthegenital
tract and genital lymph nodes [22, 67]. In fact, the viral RNA
levels in these tissues exceeded those found in the GI tract of
control animals [72]. This very high level of viral replication
in the vagina and genital lymph nodes is unprecedented
and suggests that in the absence of antiviral CD8+ T cells,
SIV replication in the genital tract was enhanced by prior
SHIV immunization. Since SHIV-immunized animals have
numerous SIV-speciﬁc CD4+ T cells in the vaginal mucosa
on the day of challenge [73], it seems likely that they
provide more cellular targets compared to the na¨ ıve animals,
which leads to enhanced local viral replication. This result
demonstrates that viral replication after challenge results
from a balance between SIV replication in abundant target
cells and eﬃcient killing of those infected target cells by
antiviral CD8+ T cells. In this sense, recent studies highlight
the importance of the number of eﬀector CTLs in relation
to the number of target cells (E:T ratios) to signiﬁcantly
reduce viral load in the female reproductive tract [19].
Of note, the induction of eﬀector-memory-like CD4+ T
cells in mucosal tissues might contribute to the protection
in live, attenuated SIV vaccine models [73] and in HIV
controllers [74]. Although the role of CD4+ T cells in viral
infection is commonly attributed to helper functions gener-
ating and supporting memory CD8+ T cell-responses [75],
antiviral cytokine production, and lytic functions have been
described in herpes simplex virus type 1, Friend leukemia
virus, and HIV infection for HIV-speciﬁc CD4+ Tc e l l s
[73].
Thus,thesamemediatorsthatinitiateimmuneactivation
leading to antiviral immune responses also activate andJournal of Biomedicine and Biotechnology 5
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Figure 1: Hypothetical model for distinct CTL response depending on the immunization strategy. (a) and (b) graphs depict both CTL
response and viremia (y-axes) over time (x-axes). Time (x-axes) includes the period of immunization and the period of infection after
pathogenic challenge (bright red arrow with virus illustration). A DNA prime viral vector boost strategy (a) induces blips of CTL response
after each immunization (with an associated memory response). Upon pathogenic challenge, this strategy generates a strong anamnestic
response that has greater memory than eﬀector CD8+ T-cell component, which will enhance the proliferative response and the associated
inﬂammation and immune activation. In contrast, a live, attenuated vaccine (b) generates persistent CTL response coupled to vaccine virus
replication. The continuous production of eﬀector CD8+ T cells is sustained by low level of persistent infection in diﬀerent tissues, including
the mucosa. At the time of virus challenge, the presence of local eﬀector CTLs is capable of controlling the initial focus of viral replication
with minimal proliferation, since these cells have more cytotoxic than proliferative potential.
recruit CD4+ Tcellstotissuesthatserveastheprimarytarget
cells for viral infection. Cytokines and chemokines regulate
cell migration and activation, and these molecules will also
determineantiviralT-cellfate[76,77].Moreover,theinﬂam-
matory milieu is a critical factor controlling the diﬀerentia-
tionofprimaryantiviralCD8+ Tcellsintoterminallyeﬀector
cells or long-lived memory T cells. Prolonged inﬂammation
or stimulation by the T-cell transcription factor, T-bet,
results in a predominantly short-lived, eﬀector CD8+ T-cell
populationratherthanalong-livedmemorypopulationwith
proliferative potential [78]. Thus, the CD8+ T-cell response
that is observed in the SHIV-vaccinated monkeys that are
protected from pathogenic SIVmac challenge is consistent
with an eﬀector T-cell population driven by continuous
antigen production rather than a large memory T-cell pool
associated with anamnestic proliferation (Figure 1(b)). Yet,
thepresenceofcentral-memoryTcellsinthedraininglymph
node and a balance between these cells and eﬀector CD8+ T
cells in the mucosa may be required to maintain an eﬀective
anti-SIV T cell response [24].
Finally, another way to control the number of target cells
and avoid excessive immune activation and inﬂammation
could be through the induction of regulatory T cells [79, 80].
However, the role of these regulatory T cells remains con-
troversial, since they could both reduce immune activation
and limit development of speciﬁc adaptive responses. In
this sense, elevated frequencies of regulatory cells associated
to low levels of immune activation may contribute to the
ability of some individuals to avoid HIV infection [81].
Further, after SIV challenge, a quiescent tissue environment
is actively maintained by a T-regulatory cell response that
rapidly expands to suppress immune activation preventing
the generation of more activated target cells to support
SIV replication ([60]; manuscript in preparation). Active6 Journal of Biomedicine and Biotechnology
immunoregulatory mechanisms, rather than intrinsically
attenuated innate immune responses, eﬃciently downregu-
late the robust innate immune responses that also occurs
soonafterSIVinfectionofthenaturalhost,theAfricangreen
monkey, in which persistent SIV infection is relatively non-
pathogenic [79]. Thus, it seems that the persistent, low-level
replication of SHIV infection modulates the immunological
response to pathogenic SIV challenge such that the response
resembles that of natural host nonhuman primates, where
lowlevelsofT-cellactivation,proliferation,andapoptosisare
also observed after SIV infection [82–84].
6. Concluding Remarks
From a vaccine development viewpoint, deﬁning the speciﬁc
subsetofCD8+ Tcellsthatareresponsibleforcontrolofviral
replication could inform HIV vaccine design and the search
for an immune correlate of protection. There is compelling
evidence from live, attenuated SIV vaccine models and
from the recent CMV-vector vaccine experiments that the
critical T cell is an eﬀector CD8+ T cell that does not
undergo anamnestic proliferation as detected in the blood.
Yet, the challenge exists on evaluating these responses at
mucosal level, where the picture seems to be completely
diﬀerent than the snapshot we can get from peripheral
blood. Although studying mucosal immunity is technically
challenging due to diﬃculty in obtaining samples of suﬃ-
cient quality and quantity for analysis, the need to improve
the relatively low eﬃcacy of the systemic AIDS vaccines
currently in development demands a focus on eliciting
mucosal immune responses through vaccination. Further,
a careful design of standardized protocols for collecting
and analyzing mucosal specimens in preclinical and clinical
trials is critical for assessing immunogenicity in HIV vaccine
candidates.
Although conventional vaccines attempt to elicit strong
anamnestic CD8+ T-cell responses after HIV exposure, cau-
tion may be needed in that pursuit. Lessons learnt from
successful persistent vaccines indicate that protection against
mucosal HIV transmission requires induction of resident
mucosa eﬀector CD8+ T cells but little systemic T-cell pro-
liferation [12, 13, 21]. A complex immune environment
allows memory eﬀector CD8+ T cells in the vagina on
the day of challenge to eﬀectively kill infected cells by not
providing additional substrate for virus replication [60]
whilst unique control against rectal challenge is conferred
by high-frequency SIV-speciﬁc T cells induced through
persistent CMV vectors [12, 21]. Both systems maintain
ar e s i d e n te ﬀector response indeﬁnitely that can protect
without anamnestic expansion [12, 21]. Development of
alternativestrategiestoreplicatingvaccinestoinducemucosa
immunity in the reproductive tract using adjuvants is
warranted[85].Otherroutesofvirustransmissionlikeblood
transfusions and mother-to-child may require diﬀerent
vaccination strategies. Considering the outcome of recent
clinical trials, reﬁned animal models may help to deﬁne
the type of complex immunological response an HIV/SIV
vaccine candidate may need to elicit to be eﬀective.
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